彩生活(01778.HK)3,020萬人幣收購母公司花樣年(01777.HK)旗下保險經紀公司
花樣年(01777.HK)與關連附屬公司彩生活(01778.HK)分別公布,雙方訂立股份轉讓協議。彩生活以3,020萬元人民幣(下同)收購母公司花樣年旗下深圳市中安信保險經紀公司全部股權。
中安信保險經紀於2004年在中國成立,持有保險牌照從事保險中介業務,截至去年底的除稅後純利106.4萬元,2019年則虧損37.2萬元。
彩生活指,收購事項將為公司提供內部保險經紀,為不同業務提供保險經紀服務,及對所管理物業的業主提供財產、汽車、人壽、醫療及其他保險服務的保險經紀服務,並預期目標公司的線上保險銷售資質可為集團線上服務平台的發展形成互補。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.